_The path of hope
for conquering cancer_
_The path of hope
for conquering cancer_
iPS-NKT: induced pluripotent stem cells (iPSC) derived natural killer T-cell (NKT cell) therapy
iPS-NKT is a novel allogeneic cell therapy agent that uses NKT cells induced from iPS cells for cancer treatment. NKT cells, which are thought to have multifaceted anti-tumor effects but are difficult to apply to cell therapy agent because only a few exist in blood, can now be produced in large quantities and homogeneously from the iPS Master Cell Bank derived from the blood of healthy donors using iPS cell technology
Cell Therapy
Empower immune cells with enhanced cytotoxicity, durability, trafficking etc. by gene modification and increase anti-tumor efficacy
Antibody
Antibodies against immune checkpoint or immune modulator that turns on/off the immune system
Cancer Vaccine
Increase the exposure of tumor-specific antigens so that the immune system can better target them
2024.12.13
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell（222KB）2024.12.10
BrightPath Presented the Preclinical Data of BP1223 in Blood Cancer at ASH 2024（89KB）2024.12.03
BrightPath to Update the Preclinical Data of BP1210 in Blood Cancer at JSI 2024（115KB）